Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21065456 | 1.00 | KDM4E (0.51) | KDM4ELMNATSHRDHODHALDH1A1 | |
| SCHEMBL30271652 | 0.94 | KDM4E (0.48) | KDM4ELMNATSHRDHODHALDH1A1 | |
| SCHEMBL30271650 | 0.94 | KDM4E (0.48) | KDM4ELMNATSHRDHODHALDH1A1 | |
| SCHEMBL21065473 | 0.92 | KDM4E (0.51) | KDM4ELMNATSHRDHODHALDH1A1 | |
| SCHEMBL21065457 | 0.92 | KDM4E (0.51) | KDM4ELMNATSHRDHODHALDH1A1 | |
| SCHEMBL951984 | 0.82 | LMNA (0.55) | KDM4ELMNAALDH1A1HPGDMAPT | |
| SCHEMBL30604082 | 0.80 | KDM4E (0.79) | KDM4ELMNADHODHALDH1A1HPGD | |
| SCHEMBL30604207 | 0.80 | KDM4E (0.79) | KDM4ELMNADHODHALDH1A1HPGD | |
| SCHEMBL2548727 | 0.80 | ALDH1A1 (0.45) | KDM4ELMNATSHRDHODHALDH1A1 | |
| SCHEMBL19732877 | 0.80 | AGTR1 (0.47) | KDM4ELMNATSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11596626-B2 | Compound for use against pathogenic Neisseria and Haemophilus species and Moraxella catarrhalis | Universität Konstanz (DE) | 2023-03-07 | — | — | US | disclosed |
| US-20210169869-A1 | Compound for Use Against Pathogenic Neisseria and Haemophilus Species and Moraxella Catarrhalis | Universität Wien (AT) | 2021-06-10 | — | — | US | disclosed |
| EP-3728193-A1 | COMPOUND FOR USE AGAINST PATHOGENIC NEISSERIA AND HAEMOPHILUS SPECIES AND MORAXELLA CATARRHALIS | Universität Konstanz (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3502095-A1 | COMPOUND FOR USE AGAINST PATHOGENIC NEISSERIA AND HAEMOPHILUS SPECIES AND MORAXELLA CATARRHALIS | Universität Konstanz (DE) | 2019-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596626-B2 | Compound for use against pathogenic Neisseria and Haemophilus species and Moraxella catarrhalis | MLEC, MPO, B3GNT2 | KDM4E 3329/4885LMNA 1268/4885TSHR 4709/4885 |
| US-20210169869-A1 | Compound for Use Against Pathogenic Neisseria and Haemophilus Species and Moraxella Catarrhalis | MLEC, MPO, B3GNT2 | KDM4E 3329/4885LMNA 1268/4885TSHR 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.